DaVita HealthCare Partners Inc. (DVA) Scheduled to Post Quarterly Earnings on Tuesday
DaVita HealthCare Partners Inc. (NYSE:DVA) is scheduled to be announcing its earnings results after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of $0.94 per share for the quarter.
DaVita HealthCare Partners (NYSE:DVA) last posted its earnings results on Tuesday, August 1st. The company reported $0.92 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.90 by $0.02. DaVita HealthCare Partners had a return on equity of 14.02% and a net margin of 8.68%. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the company earned $1.01 earnings per share. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, analysts expect DaVita HealthCare Partners to post $3.59 EPS for the current fiscal year and $3.79 EPS for the next fiscal year.
DaVita HealthCare Partners Inc. (NYSE DVA) opened at 61.07 on Tuesday. The stock has a 50 day moving average price of $58.99 and a 200-day moving average price of $62.22. The company has a market cap of $11.68 billion, a price-to-earnings ratio of 9.30 and a beta of 0.90. DaVita HealthCare Partners Inc. has a 12-month low of $53.58 and a 12-month high of $70.16.
DaVita HealthCare Partners announced that its Board of Directors has approved a share repurchase program on Tuesday, October 10th that authorizes the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.
A number of analysts have recently commented on the company. Wolfe Research raised DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating in a research report on Monday, October 23rd. Jefferies Group LLC reissued a “hold” rating and issued a $70.00 price target on shares of DaVita HealthCare Partners in a research report on Thursday, August 3rd. Zacks Investment Research cut DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. KeyCorp reissued a “hold” rating on shares of DaVita HealthCare Partners in a research report on Tuesday, October 10th. Finally, TheStreet cut DaVita HealthCare Partners from a “b” rating to a “c+” rating in a research report on Wednesday, August 2nd. Four research analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $65.00.
DaVita HealthCare Partners Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.